Based on current estimates the number of new colorectal cancer diagnoses will exceed one million over the next seven years. More than half of these patients will be treated with a highly active platinum compound called oxaliplatin. While the approved use of oxaliplatin has, for the first time in over 50 years, improved overall survival, the high incidence of oxaliplatin-induced peripheral neuropathy (and the absence of any preventive strategy) limits the clinical utility of this drug. As such, effective prophylaxis against this toxicity should still be considered a priority for innovative prevention research.
Buy this Article